Blood thinners and antiplatelets

In short

If you take a medication that affects clotting — warfarin, a direct oral anticoagulant such as apixaban or rivaroxaban, aspirin, or one of the antiplatelets like clopidogrel — the plan around your coloscopy is decided jointly between the doctor who prescribes the medication and the endoscopist. The decision balances two real risks: bleeding from a polyp removal during the test, and a clot if the medication is paused. There is no single answer that fits everyone. Do not change your dose without speaking to your prescribing clinician.

What this page covers

Why holding a blood thinner for a coloscopy is not automatic, the framework gastroenterology and cardiology societies use to make this decision, the medications most often involved, and what to bring to the conversation.

How procedure risk and thrombotic risk are weighed against each other
Antiplatelets — aspirin, clopidogrel, prasugrel, ticagrelor
Warfarin and the role of bridging
Direct oral anticoagulants (DOACs)
Diagnostic vs therapeutic coloscopy and what changes
What to ask before you stop or continue

The framework: two risks, weighed

The American Society for Gastrointestinal Endoscopy, the European Society of Gastrointestinal Endoscopy together with the British Society of Gastroenterology, and the relevant cardiology societies have all published consensus guidance on managing antithrombotic medications around endoscopy. The frameworks differ in detail but share the same logic.

Procedures are stratified by bleeding risk. A diagnostic coloscopy with biopsies is low-risk; bleeding rates are similar to those in patients not on any blood thinner. Polypectomy is higher-risk, and the risk rises further with the size of the polyp removed and the technique used (cold snare for small polyps, hot snare or endoscopic mucosal resection for larger lesions). Endoscopic submucosal dissection is highest.

Patients are stratified by thrombotic risk — the chance of a stroke, deep vein thrombosis, or stent thrombosis if the medication is held. This depends on why you are on the drug. Atrial fibrillation with a high CHA₂DS₂-VASc score, a mechanical heart valve, a recent venous thromboembolism, and a recent coronary stent are different situations from each other and from atrial fibrillation with low risk scores. The cardiology team typically owns this assessment.

The plan emerges from the intersection. A low-bleeding-risk procedure in a high-thrombotic-risk patient often means continuing the medication. A higher-bleeding-risk procedure in a low-thrombotic-risk patient often means a brief pause. Many cases sit in between, and the decision is made with both sides of the conversation talking.

Aspirin

Low-dose aspirin (often taken for established cardiovascular disease) is generally continued through a routine coloscopy in current society guidance. The bleeding risk of polypectomy on aspirin is small, and the cardiovascular risk of stopping aspirin in someone with prior cardiac stents or recent cardiovascular events can be larger.

If you take aspirin only for primary prevention — that is, to lower your risk before any cardiovascular event — your prescribing clinician may have a different view. Practice on primary-prevention aspirin has shifted in recent years.

Other antiplatelets — clopidogrel, prasugrel, ticagrelor

The thienopyridines (clopidogrel, prasugrel) and ticagrelor are stronger platelet inhibitors than aspirin and substantially raise the bleeding risk of polypectomy. The decision is highly individual. People recently fitted with a coronary stent — particularly within the first weeks to months — are usually advised to delay any non-essential elective procedure until dual antiplatelet therapy can be safely modified, because in-stent thrombosis is a serious event. People on long-standing single antiplatelet therapy more often have options.

This is exactly the conversation that needs the cardiologist and the endoscopist talking, and the patient told what they decided and why.

Warfarin

Warfarin is monitored by INR (international normalised ratio). Its effect takes days to wash out and days to come back. Periprocedural management therefore is not just about the day of the test.

For a diagnostic coloscopy without anticipated polypectomy, warfarin is sometimes continued at the patient's usual INR, particularly if INR is at the lower end of the therapeutic range. For a coloscopy where polypectomy is likely or certain, warfarin is typically held for several days before the test, with the exact number of days set by the clinical team.

A separate question is whether to bridge with a short-acting injectable anticoagulant (most often low-molecular-weight heparin) while warfarin is held. Bridging reduces the time the patient is unprotected, but it also raises bleeding risk and is not free of complications. Current consensus, supported by trial evidence, is that bridging is not routine — it is reserved for specific high-thrombotic-risk situations such as a mechanical mitral valve or a very recent venous thromboembolism. Whether to bridge, and if so how, is a decision for the team that prescribes the warfarin.

Direct oral anticoagulants (DOACs)

Apixaban, rivaroxaban, edoxaban, and dabigatran have shorter half-lives than warfarin and are not monitored by INR. They are usually held for a defined number of doses before a higher-risk procedure and restarted afterwards once haemostasis is comfortable. The exact hold is influenced by the specific drug, kidney function (which affects how quickly the drug clears, particularly for dabigatran), and the bleeding risk of the planned procedure.

The table below is directional only. Your prescribing clinician will give you specifics for your situation.

Class	Examples	Typical periprocedural pattern
Aspirin (low-dose)	Aspirin 75–100 mg	Often continued for routine coloscopy
Other antiplatelets	Clopidogrel, prasugrel, ticagrelor	Decision joint with cardiology; sometimes paused, sometimes continued, depends heavily on indication
Vitamin K antagonist	Warfarin	Continued for diagnostic only; commonly held several days before higher-bleeding-risk procedures, with bridging reserved for selected high-risk patients
DOACs	Apixaban, rivaroxaban, edoxaban, dabigatran	Continued for low-bleeding-risk procedures; doses held before higher-risk procedures, with hold length adjusted for kidney function

None of this should be turned into a self-managed plan from a table. The exact number of doses to hold, when to restart, and whether bridging applies needs the prescribing clinician.

Restarting after the procedure

The endoscopist will tell you when to resume. The choice is shaped by what was found and what was done. A polyp removed without trouble in someone whose tissue looked normal allows earlier resumption than a large or technically difficult resection where the team is watching for delayed bleeding. Late post-polypectomy bleeding can occur up to about two weeks after the procedure; resumption is staged with that in mind.

What to ask your clinician

What is the bleeding risk of the coloscopy you are planning for me — diagnostic only, or expected polypectomy?
What is my thrombotic risk if my medication is held?
Have you spoken with my cardiologist or the doctor who prescribes my anticoagulant?
If I am to hold my medication, how many doses, and when is the last one?
Will I need bridging, and if so, with what?
When do I restart after the coloscopy, and does that depend on what is done during the test?
What signs of bleeding should make me call you afterwards?
If I am on dual antiplatelet therapy after a recent stent, should this coloscopy wait?

Common worries, briefly addressed

Should I just stop a few days early to be safe?

No. Holding a medication longer than your team plans for can produce a real, avoidable thrombotic event — a stroke, a deep vein thrombosis, or stent thrombosis. The instructions you are given are calibrated. If you are unsure, ask. Do not improvise.

What if I forget and take my morning dose?

Tell the unit when you arrive. The procedure may go ahead anyway depending on what you took and what is planned, or the team may rebook you. They have seen this many times.

I have atrial fibrillation. Can I just do a stool test instead?

You can have a conversation about whether stool-based screening (such as a faecal immunochemical test, often abbreviated FIT) is reasonable for you. A positive result on a stool test still leads back to coloscopy, so the question is really one of pretest probability, not avoidance. See alternatives to coloscopy.

Is a small polyp safe to remove on my medication?

For very small polyps, cold snare polypectomy without holding antithrombotics is increasingly used and the bleeding risk is low. This decision belongs to the endoscopist at the time, with knowledge of your medication regimen.

What about herbal supplements and fish oil?

Some supplements (ginkgo, garlic in high doses, high-dose fish oil, turmeric in concentrated form) are sometimes asked about. Bring a complete list of everything you take to the pre-procedure call. The team will tell you what they want held.

Sources

American Society for Gastrointestinal Endoscopy — guidelines on the management of antithrombotic agents for endoscopic procedures
European Society of Gastrointestinal Endoscopy and British Society of Gastroenterology — joint guidance on endoscopy in patients on antiplatelet or anticoagulant therapy
American College of Cardiology / American Heart Association — periprocedural management of antithrombotic therapy
National Institute for Health and Care Excellence — guidance on atrial fibrillation and on venous thromboembolism
European Society of Cardiology — guidelines on atrial fibrillation and on antithrombotic therapy